Small Bowel Neuroendocrine Tumor Metastases: Comparison of Contrast-Enhanced Computed Tomography and 68Ga-DOTATATE PET/CT

#2805

Introduction: Most gastrointestinal neuroendocrine tumors (GI-NETs) involve the small intestine (38%) and about 50% of patients present with regional or distant metastases at time of diagnosis [2]. 68Ga-DOTATATE PET/CT provides improved sensitivity and specificity compared to traditional nuclear medicine techniques [4]. However, there is relatively less data comparing performance of 68Ga-DOTATATE PET/CT with contrast-enhanced CT (CECT).

Aim(s): To compare the performance of CECT and 68Ga-DOTATATE PET/CT for detecting small bowel NET metastases.

Materials and methods: Patients with a 68Ga-DOTATATE PET/CT between 11/2016-12/2017 and CECT of the abdomen/pelvis within three months of the PET/CT were included. Board-certified radiologists, two nuclear and two abdominal independently reviewed the imaging blinded, noting the presence of metastases: liver, spleen, bone, peritoneum, and lymph nodes: mesenteric, retroperitoneal, upper abdominal, iliac chain.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Monahan H, Packard A, Broski S, Goenka A, Kendi T,

Keywords: dotate, computed tomography, neuroendocrine tumor, small bowel, liver, lymph node, 68-gallium,

To read the full abstract, please log into your ENETS Member account.